Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580542 | 0.84 | CES1 (0.69) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL27816075 | 0.81 | CES1 (0.40) | CES1KCNN4KMT2AHDAC8HDAC6 | |
| SCHEMBL1053505 | 0.81 | CES1 (0.59) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL1585516 | 0.79 | CES1 (0.68) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL18300624 | 0.78 | MAPT (0.53) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL27916287 | 0.78 | CES1 (0.56) | CES1KCNN4MAPTKMT2ATSHR | |
| SCHEMBL27819713 | 0.78 | KCNN4 (0.47) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL6964069 | 0.78 | CES1 (0.66) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL2586906 | 0.78 | CES1 (0.66) | CES1KCNN4MAPTKMT2ASRC | |
| SCHEMBL21610298 | 0.76 | CES1 (0.63) | CES1KCNN4MAPTKMT2ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2776404-B1 | HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE | UNIV CONNECTICUT (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-3030556-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015039758-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-26 | — | — | WO | disclosed |
| US-8853228-B2 | Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase | UNIVERSITY OF CONNECTICUT (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2776404-A1 | HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE | University of Connecticut (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040102458-A1 | Small molecule compositions for binding to hsp90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-05-27 | — | — | US | disclosed |
| EP-1335920-A2 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | Sloan-Kettering Institute For Cancer Research (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002036075-A2 | SMALL MOLECULE COMPOSITIONS FOR BINDING TO HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0983507-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| EP-0441226-A1 | (cyanomethyl)pyridines useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1991-08-14 | — | — | EP | disclosed |
| US-4855476-A | 3,4-DIBENZYLOXY-5-FLUOROBENZYLCYANIDE FROM 2-FLUORO-6-METHOXYP HENOL | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4737504-A | INCREASE BETA-2 ADRENERGIC ACTIVITY WHILE DECREASING BETA-1; CARDIOVASCULAR AND RESPIRATORY DISORDERS | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1988-04-12 | — | — | US | disclosed |
| US-4625056-A | Process for producing benzene carboxylic acids from aromatic material utilizing an aliphatic organic acid agent | OCCIDENTAL RESEARCH CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP3 | CES1 3893/4885KCNN4 4814/4885MAPT 12/4885 |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | FKBP5, FKBP1A, FKBP3 | CES1 3893/4885KCNN4 4814/4885MAPT 12/4885 |
| US-20040102458-A1 | Small molecule compositions for binding to hsp90 | HSP90AB1, ERBB2, HSP90AB2P | CES1 4412/4885KCNN4 4666/4885MAPT 1645/4885 |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP1B | CES1 3402/4885KCNN4 4830/4885MAPT 11/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | CES1 3322/4885KCNN4 3071/4885MAPT 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.